ThromboGenics

Ophthalmics

ThromboGenics

ThromboGenics (NYSE: THR) is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines.

ThromboGenics (NYSE: THR) is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines.

The company’'s lead product, Jetrea (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. In Europe, it has been approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of Jetrea outside the USA. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon’s net sales of Jetrea ThromboGenics and Alcon intend to share the costs equally of developing Jetrea for a number of new vitreoretinal indications. ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), formerly referred to as TB-403, for the treatment of ophthalmic and oncology indications. ThromboGenics is headquartered in Leuven, Belgium, has commercial operations in New Jersey, U.S. and a branch in Dublin, Ireland.


Latest Articles

Who's Who

Company Spotlight

ImmunoGen

ImmunoGen

Back to top